Invesaro

Stocks Health care EVAX

NASDAQ · Health care

Evaxion A/S (EVAX)

Evaxion A/S reported revenue of $7.5M in fiscal 2025, up 125.1% from a year earlier. It posted a net loss of $7.7M. In fiscal 2025 capital spending exceeded operating cash flow by $6.6M. At December 31, 2025 it held $23.2M in cash against $5.5M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 5, 2026.

Watch EVAX in 60 seconds
Price
$3.34
+2.45% on the day · September 25, 2026
52-week range $2.77 to $12.15
Market cap
$27.9M
Revenue (FY2025)
$7.5M
+125.1% year on year
Net margin
-102.4%

What Evaxion A/S does

Evaxion A/S is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker EVAX.

Revenue and profit by year

Revenue
FY22: $0 $0 FY22FY23: $73K $73K FY23FY24: $3.3M $3.3M FY24FY25: $7.5M $7.5M FY25
Net income
FY18: -$5.5M -$5.5M FY18FY20: -$11.2M -$11.2M FY20FY20: -$15M -$15M FY20FY21: -$24.5M -$24.5M FY21FY22: -$23.2M -$23.2M FY22FY23: -$22.1M -$22.1M FY23FY24: -$10.6M -$10.6M FY24FY25: -$7.7M -$7.7M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$7.5M-$9.2M-$7.7M-$0.02-$6.6M
2024$3.3M-$14.7M-$10.6M-$0.20-$12.9M
2023$73K-$22.2M-$22.1M-$0.81-$17.8M
2022$0-$25.3M-$23.2M-$0.98-$26.1M
2021n/a-$25.8M-$24.5M-$1.26-$23.2M
2020n/a-$16.6M-$15M-$0.97-$12.6M

Full financial statements: income, balance sheet and cash flow

Where EVAX ranks in Health care

Revenue$7.5M
#492 of 646 in Health care · Bottom 24%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Evaxion A/S has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 14, 2026
  2. September 4, 2026
  3. August 20, 2026
  4. August 20, 2026
  5. August 17, 2026
  6. August 14, 2026
  7. July 17, 2026
  8. July 13, 2026
  9. July 1, 2026
  10. June 12, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on April 24, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about EVAX

What does Evaxion A/S do?

Evaxion A/S is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker EVAX.

Is Evaxion A/S profitable?

No. In fiscal 2025 it reported a net loss of $7.7M on revenue of $7.5M.

How much revenue does Evaxion A/S make?

In fiscal 2025 Evaxion A/S reported revenue of $7.5M. That is 125.1% more than a year earlier.

When did Evaxion A/S last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 5, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 14, 2026.

Similar companies

Compare EVAX with

Compare EVAX with any company

Follow EVAX

Get an email when Evaxion A/S files with the SEC: results, executive changes, material agreements and annual reports.

Follow EVAX: get an email when it files

Where the numbers come from

Financial figures are the values Evaxion A/S tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.